- Ahead of its Investor Day, Alexion Pharmaceuticals (NASDAQ:ALXN) says it expects to boost full-year 2020 revenue guidance by more than $200M.
- 2025 Guidance: Net revenue target increased to $9B-$10B vs. $7.86B previous estimate, with at least 10% annual growth through 2025 and beyond.
- Capital returns: Roughly $3B though 2023.
- Alexion’s pipeline now includes more than 20 development programs, up from four at the end of 2017, with the potential for 10 promising launches by 2023. The company is on track to produce more than five novel INDs by 2025, including two this year.
- Presentation slides are here.
- Webcast beings at 8 ET.
- https://seekingalpha.com/news/3620035-alexion-pharmaceuticals-moves-higher-after-ambitious-agenda-on-tap-for-investor-day
Tuesday, October 6, 2020
Alexion higher after ambitious agenda on tap for Investor Day
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.